ethyl 2-[3-(2-fluorophenyl)-N-methylprop-2-ynoylamino]acetate | 406687-58-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 2-[3-(2-fluorophenyl)-N-methylprop-2-ynoylamino]acetate
• 英文别名: ethyl 2-[3-(2-fluorophenyl)prop-2-ynoyl-methylamino]acetate
• CAS: 406687-58-9
• 化学式: C₁₄H₁₄FNO₃
• 分子量: 263.268
• InChiKey: WXWBXLIMBGKLCH-UHFFFAOYSA-N

物化性质

• 沸点：
  357.4±52.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 2-[3-(2-fluorophenyl)-N-methylprop-2-ynoylamino]acetate 在 lithium hexamethyldisilazane 作用下， 生成 3-(2-Fluoro-phenyl)-1-methyl-5-oxo-2,5-dihydro-1H-pyrrole-2-carboxylic acid ethyl ester
  参考文献：
  名称：

  4,5-二取代的顺式-吡咯烷酮类作为II型17β-羟基类固醇脱氢酶的抑制剂。第3部分。确定主要候选人。

  摘要：

  研究了一系列4,5-二取代的顺式-吡咯烷酮作为17β-HSDII抑制剂，用于治疗骨质疏松症。给出了几种化合物的生化数据。选择化合物42作为主要候选化合物。

  DOI：

  10.1016/j.bmcl.2006.06.041
• 作为产物：
  描述：

  3-(2-氟苯基)丙-2-炔酸 、 肌氨酸乙酯盐酸盐 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 生成 ethyl 2-[3-(2-fluorophenyl)-N-methylprop-2-ynoylamino]acetate
  参考文献：
  名称：

  4,5-二取代的顺式-吡咯烷酮类作为II型17β-羟基类固醇脱氢酶的抑制剂。第3部分。确定主要候选人。

  摘要：

  研究了一系列4,5-二取代的顺式-吡咯烷酮作为17β-HSDII抑制剂，用于治疗骨质疏松症。给出了几种化合物的生化数据。选择化合物42作为主要候选化合物。

  DOI：

  10.1016/j.bmcl.2006.06.041

文献信息

• 17-Beta-hydroxysteroid dehydrogenase-II inhibitors
  申请人：——

  公开号：US20030087952A1

  公开（公告）日：2003-05-08

  17-beta-hydroxysteroid dehydrogenase-I1 inhibitors having the structural formula 1 wherein the phenyl group labeled A and the group —C(R 4 )(R 6 )Y are oriented cis to each other; W represents 0 or S; R 1 represents —H or optionally substituted —(C 1 -C 4 )alkyl; n represents 0 or an integer of 1-3; and R 2 represents any of a variety of substituents on ring A. R 4 generally represents —H but may be a bond terminating at the ortho position of ring A. Y represents fluorine, —OR 5 , or —SR 5 , and R 5 represents —H. optionally substituted —(C 1 -C 4 )alkyl, optionally substituted -phenyl, optionally substituted —(C 1 -C 4 )alkyl-phenyl, or optionally substituted —(C 1 -C 4 )acyl. R 6 represents any of a variety of groups as defined in the specification and claims, including heteroaryl, arylalkyl, heteroarylalkyl, arylalkenyl, heteroarylalkenyl, alkynyl, arylalkynyl, heteroarylalkynyl, aryl, and indolyl. Pharmaceutically acceptable salts and N-oxides of these materials are also included. Also claimed are pharmaceutical compositions containing these materials and methods of using them.

  17-beta-羟基类固醇脱氢酶I1抑制剂具有结构式1，其中苯基A和基团—C(R4)(R6)Y相对取向；W代表0或S；R1代表—H或可选择取代的—(C1-C4)烷基；n代表0或1-3的整数；R2代表环A上的各种取代基之一。R4通常代表—H，但可能是终止在环A的邻位的键。Y代表氟、—OR5或—SR5，R5代表—H、可选择取代的—(C1-C4)烷基、可选择取代的苯基、可选择取代的—(C1-C4)烷基-苯基或可选择取代的—(C1-C4)酰基。R6代表根据说明书和索赔中定义的各种基团之一，包括杂芳基、芳基烷基、杂芳基烷基、芳基烯基、杂芳基烯基、炔基、芳基炔基、杂芳基炔基、芳基和吲哚基。还包括这些物质的药用合适盐和N-氧化物。还声明包含这些物质的药物组合物和使用它们的方法。
• 17-beta-hydroxysteroid dehydrogenase-II inhibitors
  申请人：Bayer Pharmaceuticals Corporation

  公开号：US06784167B2

  公开（公告）日：2004-08-31

  17-beta-hydroxysteroid dehydrogenase-II inhibitors having the structural formula wherein the phenyl group labeled A and the group —C(R4)(R6)Y are oriented cis to each other; W represents O or S; R1 represents —H or optionally substituted —(C1-C4)alkyl; n represents 0 or an integer of 1-3; and R2 represents any of a variety of substituents on ring A. R4 generally represents —H but may be a bond terminating at the ortho position of ring A. Y represents fluorine, —OR5, or —SR5, and R5 represents —H, optionally substituted —(C1-C4)alkyl, optionally substituted -phenyl, optionally substituted —(C1-C4)alkyl-phenyl, or optionally substituted —(C1-C4)acyl. R6 represents any of a variety of groups as defined in the specification and claims, including heteroaryl, arylalkyl, heteroarylalkyl, arylalkenyl, heteroarylalkenyl, alkynyl, arylalkynyl, heteroarylalkynyl, aryl, and indolyl. Pharmaceutically acceptable salts and N-oxides of these materials are also included. Also claimed are pharmaceutical compositions containing these materials and methods of using them.

  具有以下结构式的17-beta-羟基类固醇脱氢酶-II抑制剂，其中标记为A的苯基和群体—C（R4）（R6）Y定向为顺式构型；W代表O或S；R1代表—H或可选取代的—（C1-C4）烷基；n代表0或1-3的整数；R2代表环A上的各种取代基。R4通常代表—H，但可能是终止于环A的邻位的键。Y代表氟，—OR5或—SR5，R5代表—H，可选取代的—（C1-C4）烷基，可选取代的苯基，可选取代的—（C1-C4）烷基-苯基或可选取代的—（C1-C4）酰基。R6代表规范和权利要求中定义的各种群体，包括杂环芳基，芳基烷基，杂环芳基烷基，芳基烯基，杂环芳基烯基，炔基，芳基炔基，杂环芳基炔基，芳基和吲哚基。还包括这些材料的药学上可接受的盐和N-氧化物。还声明了含有这些材料的制药组合物和使用它们的方法。
• 4,5-Disubstituted cis-pyrrolidinones as inhibitors of 17β-hydroxysteroid dehydrogenase II. Part 1: Synthetic approach
  作者：James H. Cook、Jeremy Barzya、Catherine Brennan、Derek Lowe、Yamin Wang、Anikó Redman、William J. Scott、Jill E. Wood

  DOI：10.1016/j.tetlet.2005.01.003

  日期：2005.2

  17beta-Hydroxysteroid dehydrogenase II (17beta-HSD II) antagonists may provide an important way into preventing the onset of osteoporosis. The discovery of 4,5-disubstituted eis-pyrrolidinones as 17beta-HSD II inhibitors led to the development of an efficient intramolecular Michael addition, followed by catalytic hydrogenation to obtain the desired cis configuration. (C) 2005 Elsevier Ltd. All rights reserved.
• 17-BETA-HYDROXYSTEROID DEHYDROGENASE-II INHIBITORS
  申请人：Bayer Pharmaceuticals Corporation

  公开号：EP1326829A2

  公开（公告）日：2003-07-16
• US6784167B2
  申请人：——

  公开号：US6784167B2

  公开（公告）日：2004-08-31